HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrew Blauvelt Selected Research

deucravacitinib

7/2022Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
1/2022Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrew Blauvelt Research Topics

Disease

99Psoriasis (Pustulosis Palmaris et Plantaris)
12/2022 - 10/2002
27Atopic Dermatitis (Atopic Eczema)
08/2022 - 02/2003
19Infections
03/2022 - 03/2002
12Inflammation (Inflammations)
01/2022 - 10/2002
11Neoplasms (Cancer)
06/2022 - 04/2003
7Eczema
05/2022 - 12/2016
7Conjunctivitis
09/2021 - 12/2016
7Injection Site Reaction
09/2021 - 12/2016
7HIV Infections (HIV Infection)
01/2013 - 08/2002
6Pruritus (Itching)
11/2021 - 12/2016
5Psoriatic Arthritis
04/2022 - 08/2015
5Skin Diseases (Skin Disease)
03/2022 - 10/2009
4Body Weight (Weight, Body)
06/2022 - 01/2017
4Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
06/2022 - 07/2016
4Oral Candidiasis (Thrush)
03/2022 - 01/2021
4Pain (Aches)
11/2021 - 01/2017
4Candidiasis (Moniliasis)
10/2016 - 11/2010
3Erythema
11/2021 - 02/2018
3Rheumatoid Arthritis
03/2021 - 01/2017
3Asthma (Bronchial Asthma)
01/2021 - 10/2017
3Respiratory Tract Infections (Respiratory Tract Infection)
01/2021 - 10/2020
3Communicable Diseases (Infectious Diseases)
01/2021 - 03/2004
3Nasopharyngitis
01/2021 - 01/2016
2Skin Neoplasms (Skin Cancer)
02/2020 - 10/2016
2Crohn Disease (Crohn's Disease)
02/2020 - 01/2019
2Hepatitis B
10/2016 - 01/2012
2Soft Tissue Infections
08/2013 - 05/2010
2Contact Dermatitis (Eczema, Contact)
03/2012 - 09/2011
2Hyperplasia
02/2011 - 11/2010
1Cytopenia
06/2022
1Mycoses (Diseases, Fungus)
03/2022
1Bullous Pemphigoid (Pemphigoid)
01/2022
1Carcinogenesis
01/2022
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2021

Drug/Important Bio-Agent (IBA)

26Interleukin-17 (Interleukin 17)IBA
03/2022 - 12/2007
24Monoclonal AntibodiesIBA
11/2020 - 10/2009
23ixekizumabIBA
06/2022 - 12/2014
20CytokinesIBA
12/2022 - 10/2002
19secukinumabIBA
06/2022 - 08/2015
18dupilumabIBA
05/2022 - 01/2016
17Immunoglobulin A (IgA)IBA
06/2022 - 10/2016
17Biological ProductsIBA
01/2022 - 06/2003
14InterleukinsIBA
12/2022 - 09/2009
14Etanercept (Enbrel)FDA Link
01/2022 - 06/2006
12Interleukin-23 (Interleukin 23)IBA
12/2022 - 12/2007
11Adalimumab (Humira)FDA Link
04/2022 - 05/2011
11Ustekinumab (CNTO 1275)FDA Link
01/2022 - 01/2012
10guselkumabIBA
06/2022 - 03/2017
7bimekizumabIBA
10/2021 - 08/2018
5Pharmaceutical PreparationsIBA
03/2022 - 02/2007
5Interleukin-13IBA
01/2020 - 01/2016
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2018 - 10/2012
4omega-Chloroacetophenone (Mace)IBA
06/2022 - 01/2019
4risankizumabIBA
06/2022 - 01/2017
4CyclinsIBA
01/2022 - 06/2003
4brodalumabIBA
05/2020 - 01/2017
4Interleukin-4 (Interleukin 4)IBA
01/2019 - 01/2016
4Immunoglobulin G (IgG)IBA
01/2018 - 01/2008
4Prostaglandins AIBA
01/2018 - 10/2012
4Interleukin-12 (IL 12)IBA
01/2018 - 10/2009
4Interleukin-22 (IL-22)IBA
02/2011 - 12/2007
3TYK2 Kinase (Tyrosine Kinase 2)IBA
07/2022 - 01/2021
3Adrenal Cortex Hormones (Corticosteroids)IBA
01/2022 - 03/2002
3upadacitinibIBA
01/2022 - 01/2021
3AntigensIBA
01/2022 - 03/2004
3Tumor Necrosis Factor InhibitorsIBA
01/2021 - 01/2012
3Certolizumab PegolFDA Link
01/2019 - 08/2018
3VaccinesIBA
01/2019 - 12/2005
3Methotrexate (Mexate)FDA LinkGeneric
10/2016 - 06/2006
3Infliximab (Remicade)FDA Link
08/2013 - 05/2010
3DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
03/2008 - 08/2002
2abrocitinibIBA
08/2022 - 01/2022
2deucravacitinibIBA
07/2022 - 01/2022
2Janus KinasesIBA
01/2022 - 01/2021
2Janus Kinase InhibitorsIBA
01/2022 - 01/2021
2Interleukin-23 Subunit p19IBA
08/2021 - 10/2009
2AntibodiesIBA
01/2019 - 10/2018
2Interleukin-4 Receptors (Interleukin 4 Receptor)IBA
01/2019 - 12/2016
2Interleukin-17 ReceptorsIBA
12/2018 - 01/2018
2Interleukin-10 (Interleukin 10)IBA
07/2015 - 10/2002
2efalizumab (Raptiva)FDA Link
05/2008 - 02/2007
2DNA (Deoxyribonucleic Acid)IBA
01/2008 - 10/2002
2C-Type Lectins (C-Type Lectin)IBA
12/2005 - 03/2004
1mirikizumabIBA
12/2022
1Janus Kinase 1IBA
08/2022
1apremilastIBA
07/2022
1Adenosine Triphosphate (ATP)IBA
01/2022
1KalininIBA
01/2022
1ropsacitinibIBA
01/2022
1Imiquimod (Aldara)FDA LinkGeneric
01/2022
1AutoantigensIBA
01/2022
1src-Family KinasesIBA
11/2021
1Ointments (Pastes)IBA
11/2021
1TubulinIBA
11/2021

Therapy/Procedure

28Therapeutics
03/2022 - 05/2008
5Biological Therapy
10/2021 - 08/2013
2Critical Care (Surgical Intensive Care)
01/2021 - 12/2020
1Oral Hygiene (Dental Hygiene)
03/2022
1Retreatment
01/2022
1Drug Tapering
01/2022